Journal of Adolescent Health
Volume 44, Issue 1 , Pages 33-40 , January 2009

Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine in Healthy Boys Aged 10–18 Years

  • Tiina Petäjä, M.D.

      Affiliations

    • School of Public Health, 33014 University of Tampere, Tampere, Finland
    • ,
  • Heli Keränen, M.D.

      Affiliations

    • School of Public Health, 33014 University of Tampere, Tampere, Finland
    • ,
  • Tiina Karppa, M.D.

      Affiliations

    • University of Tampere, Medical School, Tampere, Finland
    • ,
  • Anna Kawa, M.D.

      Affiliations

    • School of Public Health, 33014 University of Tampere, Tampere, Finland
    • ,
  • Sirkku Lantela, M.D.

      Affiliations

    • School of Public Health, 33014 University of Tampere, Tampere, Finland
    • ,
  • Mari Siitari-Mattila, M.D.

      Affiliations

    • School of Public Health, 33014 University of Tampere, Tampere, Finland
    • ,
  • Helena Levänen, M.D.

      Affiliations

    • Mikkeli Municipal Health Center, Mikkeli, Finland
    • ,
  • Tuomas Tocklin, M.D.

      Affiliations

    • School of Public Health, 33014 University of Tampere, Tampere, Finland
    • ,
  • Olivier Godeaux, M.D.

      Affiliations

    • GlaxoSmithKline Biologicals, Rixensart, Belgium
    • ,
  • Matti Lehtinen, M.D., Ph.D.

      Affiliations

    • School of Public Health, 33014 University of Tampere, Tampere, Finland
    • Corresponding Author InformationAddress correspondence to: Matti Lehtinen, M.D., Ph.D., School of Public Health, University of Tampere, Sorinkatu 1, 33014 Tampere, Finland.
    • ,
  • Gary Dubin, M.D.

      Affiliations

    • GlaxoSmithKline Biologicals, King of Prussia, Pennsylvania

Received 8 July 2008 ,Accepted 6 October 2008.

References 

  1. Wallin KL, Wiklund F, Angström T, et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med. 1999;341:1633–1638
  2. Dillner J, Lehtinen M, Björge T, et al. Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer. J Natl Cancer Inst. 1997;89:1293–1299
  3. Lehtinen M, Dillner J, Knekt P, et al. Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case–control study. BMJ. 1996;312:537–539
  4. Mork J, Lie A-K, Glattre E, et al. Human papillomavirus as a risk factor for squamous-cell carcinoma of the head and neck cancer. N Engl J Med. 2001;344:1125–1131
  5. Bjørge T, Engeland A, Luostarinen T, et al. Human papillomavirus infection as a risk factor for anal and perianal cancer in a prospective study. Br J Cancer. 2002;87:61–64
  6. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–19
  7. Shah KV. Human papillomaviruses and anogenital cancers. N Engl J Med. 1997;337:1386–1388
  8. Parkin DM, Bray F. The burden of HPV-related cancers. Vaccine. 2006;24(Suppl 3):S11–S25
  9. Brown DR, Shew ML, Qadadri B, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis. 2005;191:182–192
  10. Kahn JA. Vaccination as a prevention strategy for human papillomavirus-related diseases. J Adolesc Health. 2005;37(6 Suppl):S10–S16
  11. Moscicki AB. Impact of HPV infection in adolescent populations. 7 J Adolesc Health. 2005;3(6 Suppl):S3–S9
  12. Nielson CM, Flores R, Harris RB, et al. Human papillomavirus prevalence and type distribution in male anogenital sites and semen. Cancer Epidemiol Biomarkers Prev. 2007;16(6):1107–1114
  13. Collins S, Mazloomzadeh S, Winter H, et al. High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG. 2002;109:96–98
  14. http://www.stakes.fi
  15. Krüger Kjaer S, Munk C, Falck Winther J, et al. Acquisition and persistence of human papillomavirus infection in younger men: a prospective follow-up study among Danish soldiers. Cancer Epidemiol Biomarkers Prev. 2005;14:1528–1533
  16. The Future II Study Group . Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915–1927
  17. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369:2161–2170
  18. Descamps D, Hardt K, Spiessens B, et al. Safety of human papillomavirus (HPV)-16/18 AS04 adjuvanted vaccine for cervical cancer prevention: integrated summary of 11 clinical trials. 26th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID). May 13–16 Austria: Graz; 2008;
  19. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247–1255
  20. Harper D, Gall S, Naud P, et al. Sustained immunogenicity and high efficacy against HPV-16/18 related cervical neoplasia: Long-term follow up through 6.4 years in women vaccinated with Cervarix™ (GSK's HPV 16/18 AS04 candidate vaccine). Gynecol Oncol. 2008;109:158
  21. French KM, Barnabas RV, Lehtinen M, et al. Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland. Br J Cancer. 2007;96:514–518
  22. Kim JJ, Andres-Beck B, Goldie SJ. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer. 2007;97:1322–1328
  23. Pedersen C, Petaja T, Strauss G, et al. Immunization of early adolescent women with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health. 2007;40:564–571
  24. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364:1757–1765
  25. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006;118:2135–2145
  26. Frampton JE, Keating GM. Reduced-antigen, combined diphtheria, tetanus, and acellular pertussis vaccine (Boostrix™). A review of its use as a single-dose booster immunization. Biodrugs. 2006;20:371–389
  27. Giannini SL, Hanon E, Moris P, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine. 2006;24:5937–5949
  28. Burchell AN, Richardson H, Mahmud SM, et al. Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study young women in Montreal, Canada. Am J Epidemiol. 2006;163:534–543
  29. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13:28–41
  30. Barnabas RV, Laukkanen P, Koskela P, et al. Epidemiology of HPV-16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med. 2006;3:e138

PII: S1054-139X(08)00434-5

doi: 10.1016/j.jadohealth.2008.10.002

Journal of Adolescent Health
Volume 44, Issue 1 , Pages 33-40 , January 2009

Article Tools

* Image Usage & Resolution